For research use only. Not for therapeutic Use.
Alloxazine is a selective A2b antagonist. Alloxazine completely block 5’N-Ethylcarboxamido adenosine (NECA)-mediated cyclic AMP accumulation with an IC50 of 2.9 μM. Alloxazine can be used for the research of cancer[1][2].
Alloxazine (0-30 μM, 20 min) inhibits cyclic AMP production in PGT-β cells[1].
Alloxazine (1 µmol/L; cortical surface suffusion for 0-20 min) suppresses NECA-induced vasodilation[2].
| Catalog Number | R020386 |
| CAS Number | 490-59-5 |
| Synonyms | 1H-benzo[g]pteridine-2,4-dione |
| Molecular Formula | C10H6N4O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C10H6N4O2/c15-9-7-8(13-10(16)14-9)12-6-4-2-1-3-5(6)11-7/h1-4H,(H2,12,13,14,15,16) |
| InChIKey | HAUGRYOERYOXHX-UHFFFAOYSA-N |
| SMILES | C1=CC=C2C(=C1)N=C3C(=N2)NC(=O)NC3=O |
| Reference | [1]. Brackett LE, Daly JW. Functional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts. Biochem Pharmacol. 1994 Mar 2;47(5):801-14. [2]. Shin HK, et al. Role of adenosine A(2B) receptors in vasodilation of rat pial artery and cerebral blood flow autoregulation. Am J Physiol Heart Circ Physiol. 2000 Feb;278(2):H339-44. |
